The Re-Prosper HF Study

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 125 participants.

Also called NCT04551222

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 125 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04551222
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04551222. Randomized; quadruple masking; primary purpose treatment. Start 2021-06-09 (actual); primary completion 2025-12-31 (actual). Results posted on 2026-09-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Re-Prosper HF Study
Acronym
Re-Prosper HF
Condition
Heart Failure
Intervention (Drug)
probenecid
Intervention (Drug)
Placebo
Lead sponsor
VA Office of Research and Development (class: US federal agency)

Record details

Record id
cardio:ct-nct04551222
Content hash
7ee9b017bf6eada4ba655d1afa829377a15884149fe03a4ee217edbaffdc337b